DE602006017175D1 - 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-dien zur anwendung in der behandlung von prostata-erkrankungen - Google Patents

3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-dien zur anwendung in der behandlung von prostata-erkrankungen

Info

Publication number
DE602006017175D1
DE602006017175D1 DE602006017175T DE602006017175T DE602006017175D1 DE 602006017175 D1 DE602006017175 D1 DE 602006017175D1 DE 602006017175 T DE602006017175 T DE 602006017175T DE 602006017175 T DE602006017175 T DE 602006017175T DE 602006017175 D1 DE602006017175 D1 DE 602006017175D1
Authority
DE
Germany
Prior art keywords
diene
treatment
methods
androsta
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017175T
Other languages
English (en)
Inventor
Angela Brodie
Vincent Njar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of DE602006017175D1 publication Critical patent/DE602006017175D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006017175T 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-dien zur anwendung in der behandlung von prostata-erkrankungen Active DE602006017175D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
DE602006017175D1 true DE602006017175D1 (de) 2010-11-11

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017175T Active DE602006017175D1 (de) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-dien zur anwendung in der behandlung von prostata-erkrankungen

Country Status (22)

Country Link
US (1) US7875599B2 (de)
EP (2) EP2206719B1 (de)
JP (2) JP5130453B2 (de)
KR (1) KR101380959B1 (de)
CN (2) CN101155823A (de)
AT (1) ATE482969T1 (de)
AU (1) AU2006218711B2 (de)
BR (1) BRPI0607523A2 (de)
CA (1) CA2599953C (de)
DE (1) DE602006017175D1 (de)
DK (2) DK1853619T3 (de)
EA (1) EA019560B1 (de)
ES (2) ES2528055T3 (de)
HK (1) HK1115387A1 (de)
IL (3) IL185608A (de)
MX (1) MX2007010593A (de)
NZ (1) NZ561571A (de)
PL (2) PL2206719T3 (de)
PT (2) PT2206719E (de)
SI (2) SI2206719T1 (de)
WO (1) WO2006093993A1 (de)
ZA (1) ZA200708106B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
JP5130453B2 (ja) * 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド,ボルティモア 新規なc−17−ヘテロアリールステロイドcyp17阻害剤/抗アンドロゲン:合成、インビトロ生物活性、薬物動態および抗腫瘍活性
WO2008154402A2 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20110105445A1 (en) * 2008-03-12 2011-05-05 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
CN102282133A (zh) * 2008-10-28 2011-12-14 生物马林药物股份有限公司 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂
WO2010091299A2 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
JP2012516900A (ja) * 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ,インク. ステロイド性cyp17阻害剤/抗アンドロゲン剤の新しいプロドラッグ
CA2765983C (en) 2009-06-26 2017-11-14 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
US20120282331A1 (en) * 2009-11-13 2012-11-08 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
EP2506855A4 (de) * 2009-11-30 2014-07-30 Harbor Biosciences Inc Antikarzinomverbindungen und screeningverfahren
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
AU2011343637A1 (en) * 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
AU2012284053A1 (en) * 2011-07-18 2014-01-23 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
JP2015503508A (ja) * 2011-12-22 2015-02-02 トーカイ ファーマシューティカルズ,インク. PI3K/mTOR阻害剤を使用する併用療法のための方法および組成物
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
JP6417392B2 (ja) * 2013-04-04 2018-11-07 ユニバーシティ オブ メリーランド,ボルチモア 強力なアンドロゲン受容体ダウンレギュレーションおよび抗前立腺ガン活性を伴う非ステロイド化合物およびステロイド化合物
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ, インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
EP3087080B1 (de) 2013-12-24 2018-11-28 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法
EP3294298A4 (de) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
US11390645B2 (en) 2016-08-08 2022-07-19 Industriale Chimica S.R.L. Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US20210054020A1 (en) * 2018-02-13 2021-02-25 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (de) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
ATE513555T1 (de) 2003-07-29 2011-07-15 Dompe Spa Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
JP5130453B2 (ja) 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド,ボルティモア 新規なc−17−ヘテロアリールステロイドcyp17阻害剤/抗アンドロゲン:合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Also Published As

Publication number Publication date
SI1853619T1 (sl) 2011-01-31
EP2206719A2 (de) 2010-07-14
EP1853619A4 (de) 2009-08-26
KR101380959B1 (ko) 2014-04-04
NZ561571A (en) 2009-09-25
CA2599953A1 (en) 2006-09-08
BRPI0607523A2 (pt) 2009-09-08
US20080280864A1 (en) 2008-11-13
CN103349664A (zh) 2013-10-16
SI2206719T1 (sl) 2015-03-31
ZA200708106B (en) 2008-12-31
JP2008536807A (ja) 2008-09-11
DK1853619T3 (da) 2011-01-10
WO2006093993A1 (en) 2006-09-08
EP2206719A3 (de) 2011-01-05
JP5130453B2 (ja) 2013-01-30
PL1853619T3 (pl) 2011-03-31
IL185608A0 (en) 2008-01-06
EP2206719B1 (de) 2014-10-22
PL2206719T3 (pl) 2015-03-31
AU2006218711A1 (en) 2006-09-08
IL210480A0 (en) 2011-03-31
MX2007010593A (es) 2008-02-20
IL210480A (en) 2015-06-30
KR20070120119A (ko) 2007-12-21
JP2012255026A (ja) 2012-12-27
PT1853619E (pt) 2011-01-03
IL185608A (en) 2016-06-30
ATE482969T1 (de) 2010-10-15
PT2206719E (pt) 2015-02-05
EP1853619B1 (de) 2010-09-29
US7875599B2 (en) 2011-01-25
DK2206719T3 (en) 2015-01-26
CN101155823A (zh) 2008-04-02
JP5613206B2 (ja) 2014-10-22
EP1853619A1 (de) 2007-11-14
EA200701872A1 (ru) 2008-06-30
ES2528055T3 (es) 2015-02-03
HK1115387A1 (de) 2008-11-28
IL210478A0 (en) 2011-03-31
AU2006218711A2 (en) 2006-09-08
AU2006218711B2 (en) 2010-11-11
ES2353413T3 (es) 2011-03-01
CA2599953C (en) 2013-08-13
EA019560B1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
DE602006017175D1 (de) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-dien zur anwendung in der behandlung von prostata-erkrankungen
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
EP2044961A3 (de) Phospholipid-Analoga für die Behandlung von Krebs
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
EA017278B9 (ru) Соединения азаиндазола и способы применения
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
SG152237A1 (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITY OF MARYLAND, BALTIMORE, BALTIMORE, , US